Cigarette smoke may prime lung stem cells for different types of lung cancer, Hopkins study finds

Lung cancers can use two different mechanisms to evade KRAS-inhibiting drug, MIT researchers find

About 25% of lung adenocarcinomas have mutations of the gene KRAS, which drives uncontrolled cell growth. In recent years, FDA has approved two KRAS inhibitors to treat patients with specific KRAS mutations. While these drugs can work well initially, tumors almost always develop resistance to them.

October 02, 2026

Vol.52 No.36

Clinical Roundup

Johns Hopkins investigators identify a metabolic weak point in exhausted immune cells in head and neck cancer

Immune cells can reach head and neck tumors, but once there, many stop functioning. This helps explain why immunotherapy with immune checkpoint inhibitors—which have transformed treatment for some cancers—benefit only 17% to 23% of patients with head and neck squamous cell carcinoma.

October 02, 2026

Vol.52 No.36

Perspective

When did stage 3B lung cancer become “early stage”?

My recent column about Merck’s television commercial for perioperative Keytruda left me with a question I could not shake.

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (1B, 2, and 3A) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent, according to the updated exploratory results from the ADAURA phase III trial.

September 25, 2026

Vol.52 No.35

Clinical Roundup

EGFR mutation linked to dramatically increased lung cancer risk

A rare inherited mutation in the Epidermal Growth Factor Receptor gene is associated with a 25-fold increased risk of lung cancer, according to a study by investigators at Dana-Farber Cancer Institute and 23andMe Research Institute.

September 18, 2026

Vol.52 No.34

Clinical Roundup

Ris-Rez reduced risk of death by 54% vs. topotecan in patients with relapsed SCLC, phase III trial in China finds

Hansoh Pharmaceutical Group announced positive overall survival data from ARTEMIS-008, its pivotal phase III trial in China, evaluating the B7-H3-targeted antibody-drug conjugate risvutatug rezetecan (Ris-Rez) versus topotecan in patients with relapsed small cell lung cancer whose disease progressed following platinum-based first-line therapy.

September 18, 2026

Vol.52 No.34

Cigarette smoke may prime lung stem cells for different types of lung cancer, Hopkins study finds

YOU MAY BE INTERESTED IN

Lung cancers can use two different mechanisms to evade KRAS-inhibiting drug, MIT researchers find

Johns Hopkins investigators identify a metabolic weak point in exhausted immune cells in head and neck cancer

When did stage 3B lung cancer become “early stage”?

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

EGFR mutation linked to dramatically increased lung cancer risk

Ris-Rez reduced risk of death by 54% vs. topotecan in patients with relapsed SCLC, phase III trial in China finds

Renew today!

Subscriber content

Never miss an issue!

Login